Trial Profile
A study evaluating clinical outcome and the immune characteristics of chronic hepatitis C patients receiving direct-acting antivirals.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jul 2017 New trial record